- Home
- KIRK vs LSB Comparison
KIRK vs LSB Comparison
Compare KIRK & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIRK
- LSB
- Stock Information
- Founded
- KIRK 1966
- LSB 2002
- Country
- KIRK United States
- LSB China
- Employees
- KIRK N/A
- LSB N/A
- Industry
- KIRK Diversified Commercial Services
- LSB
- Sector
- KIRK Miscellaneous
- LSB
- Exchange
- KIRK Nasdaq
- LSB NYSE
- Market Cap
- KIRK 24.0M
- LSB 22.3M
- IPO Year
- KIRK 2002
- LSB N/A
- Fundamental
- Price
- KIRK $1.10
- LSB $0.94
- Analyst Decision
- KIRK Buy
- LSB
- Analyst Count
- KIRK 2
- LSB 0
- Target Price
- KIRK $4.50
- LSB N/A
- AVG Volume (30 Days)
- KIRK 261.5K
- LSB 21.6K
- Earning Date
- KIRK 06-17-2025
- LSB 07-07-2025
- Dividend Yield
- KIRK N/A
- LSB N/A
- EPS Growth
- KIRK N/A
- LSB N/A
- EPS
- KIRK N/A
- LSB N/A
- Revenue
- KIRK $431,111,000.00
- LSB $79,415,311.00
- Revenue This Year
- KIRK N/A
- LSB $39.33
- Revenue Next Year
- KIRK N/A
- LSB $75.61
- P/E Ratio
- KIRK N/A
- LSB N/A
- Revenue Growth
- KIRK N/A
- LSB N/A
- 52 Week Low
- KIRK $1.05
- LSB $0.36
- 52 Week High
- KIRK $2.50
- LSB $6.82
- Technical
- Relative Strength Index (RSI)
- KIRK 45.02
- LSB 37.29
- Support Level
- KIRK $1.05
- LSB $0.91
- Resistance Level
- KIRK $1.28
- LSB $1.03
- Average True Range (ATR)
- KIRK 0.06
- LSB 0.06
- MACD
- KIRK -0.01
- LSB 0.01
- Stochastic Oscillator
- KIRK 18.52
- LSB 43.75
About KIRK Kirkland's Inc. COMMONSTOCK
Kirkland's Inc is a specialty retailer of home decor and gifts in the United States. The company stores provide various merchandise, including holiday decor, value pricing, and a stimulating in-store and online environment that provides customers with a brand experience. The company stores also offer an assortment of holiday merchandise in seasonal periods, as well as items that are suitable for gift-giving.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.